2nd ALS Drug Development Summit

Following the approval of Amylyx's Relyvrio in the US and Canada and further FDA decisions on the horizon in 2023, the ALS drug development landscape is gaining momentum and positivity. With booming pharma investment and new biotechs entering the field, there are still crucial translational challenges to address to bridge the gap and see clinical success for the wider ALS patient population.

Returning to Boston, the timely 2nd Annual ALS Drug Development Summit is the only industry-focused conference dedicated to overcoming preclinical and clinical challenges currently facing ALS pipelines. This is your must-attend meeting showcasing the latest breakthroughs in ALS in 2022 and 2023.

URLs:
Website: https://go.evvnt.com/1485150-0?pid=10018
Tickets: https://go.evvnt.com/1485150-2?pid=10018
Brochure: https://go.evvnt.com/1485150-3?pid=10018

Prices:
Drug Developer - Conference + 2 Workshops: USD 3597.00,
Drug Developer - Conference + 1 Workshop: USD 3098.00,
Drug Developer - Conference Only: USD 2599.00,
Solution Provider - Conference + 2 Workshops: USD 5297.00,
Solution Provider - Conference + 1 Workshop: USD 4548.00,
Solution Provider - Conference Only: USD 3799.00

Speakers: Amir Lahav, Advisor for Pharma and Tech, Head of Strategic R and D, Digital Health Innovation and Corporate Strategy, Mitsubishi Tanabe Pharma, Connie Becker, Patient Advocate, Independent, Enchi Liu, Vice President, Translational Sciences, Tranquis Therapeutics Inc., Fen Huang, Associate Director, Translational Sciences, Denali Therapeutics Inc., Fernando Vieira, Chief Executive Officer and Chief Scientific Officer, ALS Therapy Development Institute, Giulio Maria Pasinetti,The Saunders Family Professor of Neurology, Icahn School of Medicine at Mount Sinai, Gwen Petersen, Patient Advocate, Independent, James Berry Chief, Division of ALS and Motor Neuron Diseases, Massachusetts General Hospital, Jeffrey Bornstein, Chief Medical Officer, Eledon Pharmaceuticals Inc., Justin Ichida, Associate Professor​, University of Southern California, Kasper Roet, PhD Chief Executive Officer, QurAlis Corp., Kevin Robinson, Patient Advocate, Independent, Li Chin Wong, Executive Director, Translational Biomarkers and Bioanalytics, Prevail, Machelle Manuel, Vice President, Head of Global Medical Affairs, Amylyx Pharmaceuticals Corp., Matija Zelic, Senior Scientist, Precision Neurology and Neuroinflammation, Cluster Sanofi, Maya Maor-Nof, Postdoctoral Fellow, Genetics, Stanford University, Olga Uspenskaya-Cadoz, Vice President, Clinical Development, Prevail Therapeutics, Paul Wicks, Advocate, Independent, Philip Green, Patient Advocate, I AM ALS, Richard Bedlack, Physician, Duke University, Robert Goldstein-Mahon, Global and US Patient Advocacy Lead, Neuromuscular, Biogen, Sabrina Paganoni, Co-Director, Neurological Clinical Research Institute, Massachusetts General Hospital, Sam Alworth, Chief Executive Officer, AcuraStem Inc., Sami Barmada, Associate Professor and Director, University of Michigan, Sandy Hinckley, Senior Director, Head of Discovery Biology, QurAlis Corp., Shaunak Dwivedi, Physician and Patient Advocate, Independent, Sophie Parmentier, Batteur VP, head of Neuromuscular Diseases Research Unit, Biogen, Stacy Lindborg, Chief Development Officer, BrainStorm Cell Therapeutics, Stephanie Fradette, Senior Director - Medical and Clinical Development, Biogen Idec, Tammy Sarnelli, Vice President, Global Head of Regulatory Affairs, Amylyx Pharmaceuticals Corp., Tim Lowrey, ALS Patient Advocatet, Independent